Roche: FDA approves cancer test
(CercleFinance.com) - Roche announces it has received FDA approval for the CINtec PLUS Cytology test as the first biomarker-based triage test for women who may have cervical pre-cancer.
Screening results are positive for the human papilloma virus (HPV) using cobas 4800 HPV.
"The CINtec PLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It enables clinicians to more confidently determine which women should be referred to immediate further diagnostic procedures, helping to prevent women from developing more advanced cervical disease," Roche said.
"To address this, Roche is dedicated to investing in next-generation biomarkers that will significantly advance screening strategies and support global efforts to eradicate this disease,” said Thomas Schinecker, CEO, Roche Diagnostics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Screening results are positive for the human papilloma virus (HPV) using cobas 4800 HPV.
"The CINtec PLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It enables clinicians to more confidently determine which women should be referred to immediate further diagnostic procedures, helping to prevent women from developing more advanced cervical disease," Roche said.
"To address this, Roche is dedicated to investing in next-generation biomarkers that will significantly advance screening strategies and support global efforts to eradicate this disease,” said Thomas Schinecker, CEO, Roche Diagnostics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.